A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

@article{Navari2007API,
  title={A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study},
  author={Rudolph M Navari and Lawrence H. Einhorn and Patrick J Loehrer and Steven D. Passik and Jake Vinson and John McClean and Naveed Mahfooz Chowhan and Nasser H Hanna and Cynthia S. Johnson},
  journal={Supportive Care in Cancer},
  year={2007},
  volume={15},
  pages={1285-1291}
}
ObjectiveThe purpose of this study is to determine the control of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC) with the combined use of palonosetron and olanzapine, and dexamethasone with the dexamethasone given on day 1 only.Materials and methodsForty chemotherapy-naive patients received on the day of chemotherapy, day 1, an anti-emetic regimen consisting of… 
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
TLDR
Investigation of efficacy and safety of preventive use of olanzapine with triplet therapy for CINV of HEC found better results than those from previously reported studies of triplet Therapy.
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
TLDR
Olanzapine was significantly better than metoclopramide in the control of breakthrough emesis and nausea in patients receiving highly emetogenic chemotherapy.
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
TLDR
Olanzapine, as compared with placebo, significantly improved nausea prevention, as well as the complete-response rate, among previously untreated patients who were receiving highly emetogenic chemotherapy.
Olanzapine combined with standard antiemetic regimens for prevention of chemotherapy therapy-induced nausea and vomiting: a single-center experience from south India.
TLDR
Olanzapine containing pre-medication regimens can reduce acute and delayed nausea and delayed vomiting and improve the QOL of cancer patients receiving highly or moderately emetogenic chemotherapeutic agents as compared to the standard pre- medicated regimens.
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan
TLDR
An olanzapine-containing regimen has better efficacy for prevention of CINV in the HEC/MEC setting and oncologists working in a limited-resource setting should be familiar with olanZapin-containing regimens.
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study
TLDR
The three-antiemetic regimen consisting of palonosetron, aprepitant, and dexamethasone was safe and effective for controlling CINV due to high-dose melphalan treatment, especially during the delayed phase.
Efficacy and Safety of Adding Olanzapine to the Standard Preventive Regimen for Chemotherapy-induced Nausea and Vomiting in Children: A Randomized Double-blind Controlled Trial
TLDR
Adding olanzapine to the standard regimen of CINV prophylaxis was only unhelpful in pediatric patients receiving moderately emetogenic chemotherapy but also associated with a higher rate of minor side effects.
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
TLDR
Olanzapine may be effective in the MEC setting and when administered at 5-mg doses, but the paucity of data leads to notable uncertainty.
Prevention of Chemotherapy-Induced Nausea and Vomiting by Olanzapine in Japanese Female Patients with Early Breast Cancer who had Poor Control with the Standard Antiemetic Regimen
TLDR
Nausea and vomiting improved in 75% and 70% of cases, respectively, despite poor control during the first chemotherapy cycle, despite treatment with olanzapine from the second cycle.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study
TLDR
Nausea was very well controlled in the patients receiving highly emetogenic chemotherapy, with no patient having nausea [0 on scale of 0–10, M.D. Anderson Symptom Inventory (MDASI)] in the acute or delayed periods.
A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV).
  • R. NavariL. Einhorn J. McClean
  • Medicine, Psychology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Olanzapine is safe and highly effective in controlling acute and delayed CINV in patients receiving highly emetogenic chemotherapy (HEC) and MEC.
A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study
TLDR
Olanzapine may be an effective agent for the prevention of chemotherapy-induced delayed emesis in cancer patients receiving their first cycle of chemotherapy consisting of cyclophosphamide, doxorubicin, platinum, and/or irinotecan.
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
TLDR
The aprepitant regimen was more effective than the control regimen for prevention of CINV in patients receiving both an anthracycline and cyclophosphamide, and both treatments were generally well tolerated.
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
TLDR
A single i.v. dose of palonosetron 0.25 mg was significantly superior to ondansetron 32 mg in the prevention of acute and delayed CINV and both treatments were well tolerated.
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
TLDR
Single-dose palonosetron was as effective as ondansetron in preventing acute CINV following HEC, and with dexamethasone pre-treatment, its effectiveness was significantly increased over ondANSetron throughout the 5-day post-chemotherapy period.
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
  • H. SchmollM. Aapro C. Chan
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
TLDR
The aprepitant regimen was superior in the acute, delayed and overall phases of chemotherapy-induced nausea and vomiting and should be considered a new standard of antiemetic therapy for cisplatin-treated patients.
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
BACKGROUND The prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy for cancer has not been studied systematically. METHODS We enrolled patients who were scheduled
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
  • P. HeskethS. Grunberg K. Horgan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.
...
...